# Neoadjuvant FOLFOX Plus Bevacizumab Chemotherapy in Patients With Locally Advanced Colon Cancer

> **NCT00826800** · NA · TERMINATED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 2 (actual)

## Conditions studied

- Colon Cancer

## Interventions

- **DRUG:** FOLFOX and bevacizumab

## Key facts

- **NCT ID:** NCT00826800
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-02
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Lack of accrual
- **Last updated:** 2015-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00826800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00826800, "Neoadjuvant FOLFOX Plus Bevacizumab Chemotherapy in Patients With Locally Advanced Colon Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00826800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*